LIFE SCIENCE SOLUTIONS

Our partners are just starting to experience the advances and potential of our products across the pharmaceutical and agricultural sectors. For healthcare we aim to improve patients’ lives by enabling safe and efficacious gene therapies, and to enable global pharmaceutical companies to release the potential of their actives. Our agrochemical product Acticote is already delivering yield improvements as an adjuvant for oilseed rape farmers in the UK.

AQHEALTH

What is AqHealth?

AqHealth is our supramolecular solution for health care, developing novel approaches to delivering medicines to patients.

AqHealth provides safe and efficacious gene delivery technology, using unique non-viral supramolecular polymer particles to unlock the potential of gene therapies for improving patient lives. We work closely with partners in the healthcare industry, developing novel and tailored approaches to delivering medicines to patients.

Why is it needed?

The promise of DNA and RNA-vaccines and therapeutics has yet to be realised for the lack of safe, efficacious, and specific delivery vectors. Viral vectors are naturally equipped to evoke maximal gene expression but are known to generate immune responses in clinical trials. In contrast, cationic polymers and lipids demonstrate superior safety but do not afford clinically relevant levels of gene expression. The efficiency of non-viral vectors is reportedly 1/10th to 1/1000th that reported for viral vectors.

Why is it unique?
AqHealth makes products more compatible for applications with formulation flexibility and improved active stability, thereby providing targeted delivery of actives on demand. In gene therapy, our non-viral vehicles have the potential to approach the performance of natural systems while less likely to trigger immunogenic responses. Our modular approach to delivery means greater flexibility to overcome significant challenges of stabilisation and delivery.

What’s the opportunity for our partners?

AqHealth, a proprietary technology, offers our partners the potential to allow new product development and patent life extension with existing actives.

£15bn

value for the advance therapeutics medicinal products market by 2020.

Acticote

What is Acticote?
Acticote is an agricultural crop adjuvant pod sealant for oilseed rape. Distributed in the EU by Intracrop, Acticote improves crop yields by reducing the incidence of pod shatter.

The Acticote active ingredient, delivered in liquid form, effectively interacts with the pod surface resulting in reduced shattering and increased yield.

Why is it needed?
A rise of >1.5°C in the global temperature is forecasted over the next 30 years. This will have a profound impact on farming and global food production. Our chemistry is at the forefront of life science solutions. The loss of earnings to farmers because of this type of harvest loss is currently estimated to be £120m pa in the UK. The average loss is ca £175/ha but this can be alleviated with the application of Acticote.

Why is it unique?
Unlike other pod sealants based on polymer film formation, Acticote offers a more environmentally friendly way to reduce pod shatter using a degradable technology without generating microplastics.

Acticote has achieved up to 18% yield increase in oil seed rape over a number of successful field trials.

What’s the opportunity for our partners?
We are looking at adapting this supramolecular chemistry to work on a number of other crops and in a variety of climates. We are seeking partners to help bring this innovation to farmers around the world and make a positive impact on the environment.

£120m

per annum is the estimated loss of earnings for UK farmers due to drying out before harvesting.

>1.5˚C

A rise of 1.5°C in the global temperature is forecast over the next 30 years. This will have a profound impact on farming and global food production. Our chemistry is at the forefront of life science solutions. *

$4.2bn

Estimated size of the global agricultural adjuvants market by 2022, growing at a compound annual growth rate of 5.9% from 2016.